

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BBI LIFE SCIENCES CORPORATION**  
**BBI生命科學有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1035)**

**APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER**

This announcement is made pursuant to Rule 2.1 of the Code on Takeovers and Mergers (the “**Takeovers Code**”).

Reference is made to the joint announcement issued by BBI Life Sciences Corporation (the “**Company**”) and LJ Future Ltd. (the “**Offeror**”) dated 20 January 2020 (the “**Joint Announcement**”) in relation to, among other things, the Offeror’s request to the Board to put forward to the Scheme Shareholders the proposed privatisation of the Company by way of a scheme of arrangement under Section 86 of the Companies Law.

Capitalised terms used in this announcement shall have the same meanings as those defined in the Joint Announcement unless otherwise stated.

**APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER**

The Board is pleased to announce that Optima Capital Limited has been appointed as the independent financial adviser (the “**Independent Financial Adviser**”) to advise the Independent Board Committee in relation to the Proposal.

Optima Capital Limited is a licensed corporation to carry out Type 1 (dealing in securities), Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities under the SFO.

The appointment of the Independent Financial Adviser has been approved by the Independent Board Committee in accordance with Rule 2.1 of the Takeovers Code. The letter of advice from the Independent Financial Adviser in respect of the Proposal will be included in the Scheme Document to be despatched to the Shareholders.

**Shareholders and potential investors should exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their stock broker, bank manager, solicitor and/or other professional advisers.**

By order of the Board  
**BBI Life Sciences Corporation**  
**Wang Qisong**  
*Chairman*

Hong Kong, 6 February 2020

*As at the date of this announcement, the executive Directors are Mr. Wang Qisong, Ms. Wang Luojia and Ms. Wang Jin, the non-executive Director is Mr. Zhou Mi, and the independent non-executive Directors are Mr. Xia Lijun, Mr. Ho Kenneth Kai Chung and Mr. Liu Jianjun.*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statement in this announcement misleading.*